Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Culturally Adapted Materials to Increase Cervical Cancer Screening Among Polish Women in Iceland

2 de octubre de 2026 actualizado por: The Primary Health Care in the Capital Area

Testing of Culturally Adapted Materials to Enhance Participation in Cervical Cancer Screening Among Polish Women Residing in Iceland

This study tests whether sending Polish women residing in Iceland a culturally adapted invitation letter - tailored in language and messaging to the target group - increases participation in cervical cancer screening compared with a standard, non-adapted invitation letter. Eligible women will be randomly assigned to receive one of the two letter types, and screening participation will be tracked over the following months.

Descripción general del estudio

Descripción detallada

It has been shown that cervical cancer screening participation remains lower among women with immigrant background, compared to the general population. Translating existing screening materials into the languages of the immigrant groups may not be sufficient to motivate screening participation. However, cultural adaptation of cancer screening materials has been suggested as a potential strategy to facilitate screening attendance.

This study investigates whether a culturally adapted invitation letter increases attendance at cervical cancer screening among Polish women residing in Iceland, compared with the standard invitation letter currently used in the national cervical cancer screening program. The adapted letter was developed in collaboration with a focus group from the target population.

All individuals registered as female in Registers Iceland and aged 23-64 years are eligible for cervical cancer screening in accordance with the national cancer screening guidelines issued by the Directorate of Health. Eligible individuals receive an invitation letter both digitally via the national health portal and by post. All eligible individuals receive digital invitations in Icelandic, English and Polish. Paper invitations are available only in Icelandic. Therefore, the culturally adapted letter will only be sent digitally.

Polish-born women residing in Iceland who are due for routine cervical cancer screening will be randomized 1:1 to receive either the culturally adapted invitation letter or the standard invitation letter.

This trial is intended to generate evidence on whether low-cost intervention, such as the cultural adaptation of existing screening materials, may help reduce disparities in screening uptake.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

2000

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Copia de seguridad de contactos de estudio

Ubicaciones de estudio

      • Garðabaer, Islandia, 210
        • Cancer Screening Coordination Center, Primary Health Care of the Capital Area

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

23 años a 64 años (Adulto)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Femenino

Descripción

Inclusion Criteria:

  • Individuals within the target population for the national cervical cancer screening program in Iceland, defined as those registered as female in the population register and aged 23-64 years
  • Born in Poland
  • Being due to be invited for cervical cancer screening during the study enrolment period, in accordance with the cervical cancer screening guidelines issued by the Directorate of Health.

Exclusion Criteria:

-Individuals who are not eligible for the national cervical cancer screening program in Iceland (non-female, outside the screening age and not due for an invitation (time since last screening attendance)).

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Investigación de servicios de salud
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Doble

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Culturally adapted invitation letter

Participants in this arm receive a screening invitation letter which has been culturally adapted, developed with community input.

Participants randomized to the intervention group will receive a screening invitation letter which has been culturally adapted, developed with community input from individuals in the target group. The letter provides information about cervical cancer screening and has been adapted to the language, cultural context, and communication needs of the target population of Polish women residing in Iceland. The adapted letter retains the essential information contained in the standard invitation while modifying its wording and presentation to improve relevance, understanding, and engagement, with the aim of increasing attendance at cervical cancer screening. The letter will be sent once digitally via the electronic health platforms heilsuvera.is and island.is.

Comparador activo: Standard cervical cancer screening invitation letter

Participants in this arm receive a standard invitation letter to cervical cancer screening.

Participants randomized to the control group will receive the standard invitation letter routinely used to invite eligible individuals to cervical cancer screening. The standard letter provides information about the screening programme and instructions for attending screening. The letter will be sent once digitally via the electronic health platforms heilsuvera.is and island.is.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Participation rate in the national cervical cancer screening program in Iceland
Periodo de tiempo: From the date the invitation is sent through 6 months post-invitation.

The primary outcome of this study will be the participation rate in the Icelandic national cervical cancer screening program within 6 months of invitation, defined as a registered cervical sample in the Icelandic Cancer Screening Register. Participation will be coded as a binary variable (yes/no).

From the date the invitation is sent through 6 months post-invitation.

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Participation rate in the national cervical cancer screening program in Iceland
Periodo de tiempo: From the date the invitation is sent through 3 months post-invitation.

The secondary outcome will be the participation rate in the Icelandic national cervical cancer screening program within 3 months of invitation, defined as a registered cervical sample in the Icelandic Cancer Screening Register. Participation will be coded as a binary variable (yes/no).

From the date the invitation is sent through 3 months post-invitation.

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Ágúst Ingi Ágústsson, Cand. Med., Cancer Screening Coordination Center, Primary Health Care of the Capital Area

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de septiembre de 2026

Finalización primaria (Estimado)

1 de enero de 2028

Finalización del estudio (Estimado)

1 de enero de 2028

Fechas de registro del estudio

Enviado por primera vez

24 de septiembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

2 de octubre de 2026

Publicado por primera vez (Actual)

5 de octubre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

5 de octubre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

2 de octubre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir